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Cardiac Function and Heart Failure
Marc A. Pfeffer, MD
Boston, Massachusetts
I had the pleasure working with Drs. Jonathan Abrams,
Howard A. Cohen, Sudhir S. Kushwaha, and Eric S.
Williams to develop the specific contributions in the broad
field of cardiac function and heart failure to be presented as
original work at these Scientific Sessions. With the assis-
tance of other highly respected reviewers, 1,143 abstracts
were graded for selection for only 351 allotted slots on the
overall program. As such, many highly ranked abstracts
were not able to be accepted for presentation. The accepted
abstracts were then assigned into thematically grouped
sessions. Although it is impossible to cover the content of
these original contributions, a brief overview of the titles of
these sessions provides some insight into the active areas of
investigation.
There were several sessions devoted to cardiomyopathies
with specific sessions for hypertrophic, dilated, and re-
stricted cardiomyopathies. The Program Committee also
had one session termed miscellaneous cardiomyopathies.
This does not indicate that the Program Committee iden-
tified a new form of cardiomyopathy, but does demonstrate
that there were many highly ranked abstracts on the issue of
cardiomyopathy that did not quite fall into one of the easily
recognized clinical patterns. Myocarditis continues to be an
important area of investigation.
Contributions concerning cardiac transplantation pro-
duced several high-quality sessions concentrating on clinical
prognostic factors for both short-term rejection and allo-
graft vasculopathy. It is noteworthy that two entire sessions
were devoted to the left ventricular assist device, providing
a flavor of the advances in this field in managing these
highest risk patients.
A substantial proportion of the accepted presentations
concentrated on the interface of cardiac function, heart
failure, and the elderly. There were particular sessions
devoted to physiologic alterations, coronary syndromes, and
specific risk factors for failure in the elderly as well as the
risk/benefits of pharmacologic therapy in this important
segment of our population. My favorite session topic was
entitled “Hazards of Being Elderly.” Although I did not
attend the specific session, I was assured that an American
Association of Retired Persons card was not required for
admission.
The number of abstract submissions and acceptances
concerning heart failure with preserved systolic function
indicates that this is a clear investigative growth area.
Exercise testing as well as exercise training continue to be
important investigative and therapeutic areas. Contributions
concerning ventricular remodeling continue to provide
mechanistic underpinnings for a broad range of areas of
cardiac function and heart failure. The prognostic impor-
tance of old standards, such as assessments of left ventricular
as well as right ventricular ejection fractions, was empha-
sized in several sessions concerning outcomes of patients
with heart failure.
The added prognostic value of a determination of B-type
natriuretic peptide (BNP) levels was a clear theme across a
strong group of accepted abstracts. Important contributions
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from Drs. McCullough and Maisel continue to lead the
field by demonstrating the utility of “point of care” evalua-
tions of BNP, particularly in the determination of whether
dyspnea was a consequence of cardiac or pulmonary disease
(1). B-type natriuretic peptide was also shown to be an
additive prognostic factor for death in patients being con-
sidered for cardiac transplantation (2). However, we are also
beginning to see the pendulum swing back a bit with an
abstract indicating that in patients with severe heart failure,
the correlation between wedge pressure and BNP was not
ideal (3). In an interesting evaluation of clinical acumen
versus the BNP analogous to the chess match between the
IBM mega-computer versus the Russian master, the physi-
cian recognition of an S3 identified those with an elevated
BNP (4). I personally chuckled when I noticed that the
senior author on this abstract was Dr. Kanu Chatterjee,
since with this leading clinical cardiologist performing the
evaluation, one could anticipate that the BNP would be
redundant!
This year’s contributions from basic investigations were
particularly strong and covered an exciting range of novel
concepts. Key studies probed the development of cardiomy-
opathies, demonstrating the signaling pathways involved in
the development of hypertrophy and remodeling. Mecha-
nisms of contractile dysfunction continue to be important
fields, which enrich our understanding of pathophysiology
of impaired pump function. Several sessions were devoted to
studies of gene transfer where contractile abnormalities are
already being selectively reversed by “genetic corrections” in
animal models. An important new area of scientific contri-
butions involves the use of novel cell therapies, which are
already showing promise in both animal and preliminary
clinical studies. Use of skeletal myoblasts, stem cells, as well
as cytokines to stimulate natural repair processes to improve
ventricular function were featured by several highly scored
abstracts.
A definitive reminder of the progress in the care of
patients with heart failure was provided by an analysis of a
Swedish National Registry of admissions and discharges
with the diagnosis of heart failure. Swedberg and co-
workers demonstrated an impressive reduction in both
in-hospital deaths and one-year mortality during and after
an admission for heart failure during the interval between
1988 and 2000 (5). For patients between 55 and 64 years of
age, one-year mortality decreased by over 50% during this
period. Even in the elderly, those 75 to 84 years, the
one-year mortality rate decreased by one-third during these
12 years. What is remarkable about these findings is that
these were non-study patients, underscoring that the bene-
fits observed in previous clinical trials have now been
translated to real-world populations!
The cardiovascular community does not rest on past
accomplishments, and at this Annual Scientific Session of
the ACC, the new trials presented at the Late-Breaking
Trial Sessions will undoubtedly favorably alter the practice
of medicine. The Eplerenone Post-AMI Heart Failure
Efficacy and Survival Study (EPHESUS) study, presented
by Dr. Bertram Pitt, demonstrated that in high-risk myo-
cardial infarction (MI) patients, those selected for pulmo-
nary congestion, either permanent or transient, as well as
reduced left ventricular ejection fraction showed a survival
improvement with the use of a selective aldosterone inhib-
itor, eplerenone. In a well-conducted multicenter,
randomized-controlled clinical trial involving over 6,000
patients, a 15% reduction in the risk of death with random-
ization to eplerenone was reported. Reductions in cardio-
vascular mortality and hospitalization were also observed,
and an intriguing reduction in the risk of sudden death with
the aldosterone antagonist was presented. Importantly,
these benefits were observed on top of conventional therapy
including beta-blocker and angiotensin-converting enzyme
inhibitors, indicating that this use of eplerenone offers a true
advance in the management of these high-risk patients. The
public health implications of EPHESUS were underscored
by another abstract presented at this meeting concerning a
registry of over 5,000 non-trial acute MI patients (6). Eric
Velazquez reported that patients having an MI complicated
by left ventricular dysfunction and/or pulmonary congestion
constitute approximately 40% of acute MI admissions and
that this group has 80% of all hospital MI deaths. There-
fore, the advance demonstrated by Dr. Pitt and his col-
leagues should have a substantial impact in reducing mor-
tality and morbidity during and after MI.
Drs. Arthur Feldman and Michael Bristow presented the
preliminary results of the Comparison of Medical Therapy,
Pacing, and Defibrillation in Chronic Heart Failure
(COMPANION) trial at one of the late-breaking sessions.
Patients with advanced heart failure and QRS interval
widening were randomized to either optimal pharmacologic
therapy, biventricular cardiac resynchronization therapy
(CRT), or CRT combined with the cardioverter-
defibrillator (CRT-D). This trial was designed to address
whether these device modalities would reduce the risk of
death and hospitalizations. The preliminary results indi-
cated that the one-year events of death or any hospitaliza-
tion was reduced by approximately 20% with CRT and
CRT-D. Similarly, death or cardiovascular hospitalization
and death or heart failure hospitalization at one year were
significantly reduced by approximately 30% to 40%. Al-
though the results are preliminary, the COMPANION trial
does indicate that in selected patients with severe heart
failure (class III and IV) and wide QRS interval, this
non-pharmacologic therapy can lead to clinical improve-
ments over and above a currently optimal medical regimen.
Cardiac function and heart failure are now demonstrating
a non-vicious cycle with positive interactions between basic
and clinical investigators. It is really becoming difficult to
ascertain whether the novel concepts are coming from the
trials or more basic studies, or vice versa. The sessions were
replete with high-quality studies, which both improved our
understanding of pathophysiology and demonstrated the
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translation of previous research into better clinical out-
comes.
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Cardiac Arrhythmias and Implantable Devices
David L. Hayes, MD
Rochester, Minnesota
Significant original research was reported at the American
College of Cardiology 2003 National Meeting in the field of
cardiac arrhythmias and implantable devices.
Cardiac resynchronization therapy (CRT) is still a topic
of great interest and rapid evolution. The initial results of
the Comparison of Medical Therapy, Pacing, and Defibril-
lation in Chronic Heart Failure (COMPANION) trial were
presented. This was the first CRT trial designed to assess
mortality. Patients were randomly assigned to optimized
medical therapy, biventricular pacing, or biventricular pac-
ing with implantable cardioverter-defibrillator (ICD) capa-
bility. The lowest mortality was observed in the group with
CRT and ICD (p  0.002). It also was noted that the
difference in response between patients with ischemic car-
diomyopathy and those with dilated cardiomyopathy was
not significant.
A question often asked about CRT is whether paced
patients who have an underlying intrinsic rhythm with a
narrow QRS interval receive benefit from an upgrade to
CRT. Oezatalay et al. (1) presented data demonstrating that
these patients not only have symptomatic improvement with
CRT but may demonstrate greater improvement than
patients with an intrinsic interventricular conduction delay
because of the potential deleterious effects of pacing from
the right ventricular apex.
A prospective trial demonstrated that patients with
chronic atrial fibrillation receive benefits from CRT similar
to those of patients in normal sinus rhythm (2). This further
supports the available data from the Multisite Stimulation
in Cardiomyopathy (MUSTIC)-Atrial Fibrillation trial.
The assessment of interventricular dyssynchrony by
pulsed wave tissue Doppler imaging and strain gauge
techniques were shown to have potential for better deter-
mining patient selection for CRT, for assisting in position-
ing the coronary venous lead, and for subsequently optimiz-
ing the left ventricular to right ventricular timing differences
(3–5).
Cardiac resynchronization therapy implant techniques,
both epicardial lead placement (6) and coronary venous lead
placement, continue to evolve. Worley et al. (7) reported on
a group of 35 patients in whom they performed coronary
venous angioplasty that subsequently allowed successful lead
placement in 70% of the group who might otherwise have
required epicardial lead placement.
Information also emerged about inflammatory markers
and neurohumoral changes after CRT. Cardiac resynchro-
nization therapy was shown to lower levels of brain natri-
uretic peptide, atrial natriuretic peptide, and endothelin-1
(8), and Theodorakis et al. (9) demonstrated lower
interleukin-6 values with CRT.
Many clinicians are struggling with the implications of
the Multicenter Automatic Defibrillator Implantation
Trial-II (MADIT-II) and how to apply these data to the
large population of patients who meet these criteria. As of
mid-2003, there is no ruling from the Centers for Medicare
and Medicaid Services, that is, MADIT-II criteria do not
represent a reimbursed criterion. Sharma et al. (10) assessed
all their patients who would meet MADIT-II criteria and
found that if applied nationally, this would lead to addi-
tional implants in approximately 460,000 patients. Other
investigators found that MADIT-II results can be general-
ized to tertiary referral centers (11), and others demon-
strated that adding bundle-branch block to the MADIT-II
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